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ABSTRACT 
This project paper discusses on patent protection and access to affordable drugs. 
Chapter one of the project paper presents a background about the laws and issues 
involved in patent protection and access to affordable drugs. Chapter two of the 
project paper discusses on the relevant TRIPS provision, the flexibilities of the 
TRIPS Agreement and the Doha Paragraph 6 System. The flexibilities of the TRIPS 
Agreement include compulsory license, government use, parallel importation and 
permitted limited exceptions. Chapter three of the project paper discusses on the 
implementation of the TRIPS Agreement in various countries, which includes the 
United States, India, Brazil, South Africa and Malaysia. Chapter four explains the 
further barriers of the implementation of the TRIPS Agreement. The final chapter 
discusses the possible alternatives in enhancing access to affordable drugs. 
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